{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:55:18Z","timestamp":1774464918487,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ijrobp.2017.06.2465","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T06:45:35Z","timestamp":1499150735000},"page":"912-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study"],"prefix":"10.1016","volume":"99","author":[{"given":"Nathalie","family":"Arians","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinhard","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Benner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Rochet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Sterzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Leitzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Lindel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.06.2465_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib2","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1001\/jama.291.22.2755","article-title":"Symptoms of ovarian cancer\u2013where to set the bar?","volume":"291","author":"Daly","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","article-title":"Prevention and early detection of ovarian cancer: Mission impossible?","volume":"174","author":"Bast","year":"2007","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib6","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group","volume":"78","author":"Aabo","year":"1998","journal-title":"Br J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ijrobp.2017.06.2465_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1008355317514","article-title":"First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer\u2013a new standard of care?","volume":"10","author":"du Bois","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib8","first-page":"34","article-title":"Chemotherapy for ovarian cancer","volume":"26","author":"Ozols","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib9","first-page":"343","article-title":"Meta-analysis of chemotherapy regimens for ovarian carcinoma: A reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide","volume":"18","author":"West","year":"1997","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib11","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3892\/or_00000479","article-title":"Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer\u2013a prospective multicenter phase II trial (PRIMOVAR)","volume":"22","author":"P\u00f6lcher","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib20","doi-asserted-by":"crossref","first-page":"129s","DOI":"10.1200\/JCO.2003.04.003","article-title":"Progress in the management of gynecologic cancer: Consensus summary statement","volume":"21","author":"Cannistra","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1048-891X.2004.014507.x","article-title":"Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: Life expectancy compared to women of an age-matched normal population","volume":"14","author":"Lambert","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0360-3016(90)90229-D","article-title":"Primary adjuvant whole abdominal irradiation in ovarian carcinoma","volume":"19","author":"Lindner","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0360-3016(01)02785-7","article-title":"Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies","volume":"52","author":"Mundt","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-8140(01)00473-X","article-title":"Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation","volume":"62","author":"Hurkmans","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ijrobp.2009.03.061","article-title":"Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin\/taxane chemotherapy for advanced ovarian cancer: Phase I study","volume":"76","author":"Rochet","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2407-11-41","article-title":"Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study","volume":"11","author":"Rochet","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pst.541","article-title":"Adaptive designs for single-arm phase II trials in oncology","volume":"11","author":"Englert","year":"2012","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib29","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0038-1635488","article-title":"Descriptive data analysis: A concept between confirmatory and exploratory data analysis","volume":"26","author":"Abt","year":"1987","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2006.07.034","article-title":"Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy","volume":"104","author":"Petit","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0360-3016(99)00227-8","article-title":"Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: Results of a prospective treatment protocol","volume":"45","author":"Wong","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0360-3016(92)90779-H","article-title":"Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer","volume":"22","author":"Whelan","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0090-8258(91)90250-9","article-title":"Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation","volume":"41","author":"Ledermann","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1525-1438.2003.13193.x","article-title":"Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment","volume":"13","author":"Sorbe","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0167-8140(99)00144-9","article-title":"Is there place for radiotherapy in the treatment of advanced ovarian cancer?","volume":"53","author":"Einhorn","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0360-3016(92)90778-G","article-title":"Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma","volume":"22","author":"Fyles","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0167-8140(93)90022-Z","article-title":"External beam radiotherapy in the management of ovarian carcinoma","volume":"26","author":"Reinfuss","year":"1993","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0360-3016(89)90113-2","article-title":"Optimal coverage of peritoneal surface in whole abdominal radiation for ovarian neoplasms","volume":"17","author":"LaRouere","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/gyno.1998.5184","article-title":"Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer","volume":"72","author":"Pickel","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2004.09.010","article-title":"Consolidative abdominopelvic radiotherapy after surgery and carboplatin\/paclitaxel chemotherapy for epithelial ovarian cancer","volume":"62","author":"Dinniwell","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0360-3016(92)90777-F","article-title":"Epithelial ovarian cancer: The role of radiotherapy","volume":"22","author":"Dembo","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0360-3016(03)00510-8","article-title":"High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: Long-term toxicity and outcomes","volume":"57","author":"Firat","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2009.11.010","article-title":"Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy","volume":"79","author":"Rose","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.06.2465_bib46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2012.04.044","article-title":"Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies","volume":"85","author":"Liang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617335484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617335484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T10:40:32Z","timestamp":1569667232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617335484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0360301617335484"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2465","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}